A heavily pretreated patient with aggressive Grade 3 non-germinal centre diffuse large B-cell lymphoma (DLBCL) achieved a complete metabolic response in the ongoing Phase I clinical trial of Lantern Pharma’s LP-284. 

Lantern uses an AI approach to determine mechanisms of action of any cancer focused molecule, identify biomarker-driven subpopulations and optimise combination strategies for the clinical setting. 

The 41-year-old patient had previously failed three aggressive treatment regimens over 18 months. These included: standard R-CHOP/Pola-R-CHP chemotherapy, CAR-T cell therapy (liso-cel), and CD3xCD20 bispecific antibody therapy (glofitamab).  

Following enrolment in April 2025, the patient achieved complete metabolic response with non-avid lesions after completing just two 28-day cycles of LP-284 administered on days one, eight, and 15. 

“This extraordinary clinical observation represents a transformative moment for our computationally guided, therapeutic development paradigm,” said Panna Sharma, President and CEO of Lantern Pharma. “This complete metabolic response in a patient who had exhausted all conventional therapeutic options strongly supports our strategic thesis that computational approaches can unlock previously inaccessible therapeutic opportunities.” 

LP-284, a computationally optimised next-generation acylfulvene, was developed to exploit synthetic lethal interactions in cancer cells harbouring specific DNA damage repair deficiencies.  

The compound represents a fundamentally different therapeutic strategy with the potential to preferentially target malignant cells while preserving healthy tissue function. 

The Phase I dose-escalation study is designed to evaluate LP-284’s safety profile, optimal dosing parameters, and preliminary efficacy signals across multiple aggressive lymphoma subtypes. 

The company anticipates providing additional clinical updates as the trial progresses and more patients reach evaluable timepoints. 

LP-284 has received multiple Orphan Drug Designations from the US Food and Drug Administration, including designations for mantle cell lymphoma and high-grade B-cell lymphomas.

Diana Turner, Senior Digital Content Editor, DDW